Antibiotic induced liver injury: What about children?

Journal of Chemotherapy

Volumn 25, Issue 5, 2013, Pages 255-272

  Serranti, Daniele ^a   Montagnani, Carlotta ^a   Indolfi, Giuseppe ^b   Chiappini, Elena ^a   Galli, Luisa ^a   de Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antibiotics; Children; Hepatotoxicity; Idiosyncratic; Macrolides; Penicillins; Sulphonamides; Tetracyclines

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; CARBAPENEM; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; HLA DRB1 ANTIGEN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PENICILLIN G; PENICILLIN V; TELITHROMYCIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ACNE VULGARIS; ANOREXIA; ASCITES; AUTOIMMUNE HEPATITIS; BACTERIAL SINUSITIS; BILE DUCT DISEASE; CHILD; CHOLESTASIS; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEVER; FULMINANT HEPATIC FAILURE; GRANULOMATOUS HEPATITIS; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LYMPHADENOPATHY; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STEATOSIS; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; URINARY TRACT INFECTION;

AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84884794989     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000090     Document Type: Review

References (169)

1. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774-85.
2. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000;15(5):480-8.
3. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145-55.
4. Larrey D. Drug-induced liver diseases. J Hepatol. 2000;32:77-88.
5. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451-5.
6. de Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8):1187-95.
7. de Abajo FJ, Montero D, Madurga M, Garci{dotless}́a Rodri{dotless}́guez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58(1):71-80.
8. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924-34.
9. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065-76.
10. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16(23):3041-53.
11. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003-9.
12. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol. 2005;39(4 Suppl 2): S83-9.
13. Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopati{dotless}́as Asociadas a Medicamentos). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 2007;150(6):808-15.
14. Fréneaux E, Labbe G, Letteron P, The Le Dinh, Degott C, Genève J, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicularsteatosis induced by this antibiotic. Hepatology. 1988;8(5):1056-62.
15. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis. 2001;12(2):113-24.
16. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958-76.
17. Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics. 2010;11(5):607-11.
18. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-9.
19. Donaldson PT, Bhatnagar P, Graham J, Henderson J, Leathart JB, Pirmohamed M, et al. Proceedings of the 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31-Nov 4; San Francisco, CA, USA. Hepatology. 2008;48:396A-7A.
20. Hautekeete ML, Horsmans Y, van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillinclavulanate-induced hepatitis. Gastroenterology. 1999;117(5): 1181-6.
21. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000;47(5):717-20.
22. Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol. 1995;22(1):71-7.
23. Levy C, Lindor KD. Drug-induced-cholestasis. Clin Liver Dis. 2003;7(2):311-30.
24. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4(1):73-96.
25. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15.
26. Lucena MI, Garci{dotless}́a-Cortés M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 2008;22(2):141-58.
27. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al.; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55-68.
28. Kramer MS. Assessing causality of adverse drug reactions: global introspection and its limitations. Drug Inf J. 1986;20:433-7.
29. Macedo AF, Marques FB, Ribeiro CF. Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs? Drug Saf. 2006;29:697-702.
30. Goldstein LI, Ishak KG. Hepatic injury associated with penicillin therapy. Arch Pathol. 1974;98(2):114-7.
31. Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci. 1981;26(5):470-3.
32. Oñ ate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, González de Zárate P, Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis. 1995;20(2):474-5.
33. Andrade RJ, Guilarte J, Salmerón FJ, Lucena MI, Bellot V. Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother. 2001;35(6):783-4.
34. Kö klü S, Yü ksel O, Filik L, Usküdar O, Altundag K, Altiparmak E. Recurrent cholestasis due to ampicillin. Ann Pharmacother. 2003;37(3):395-7.
35. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An ampicillin-associated case. Gastroenterology. 1990;99(3):854-6.
36. Davies MH, Harrison RF, Elias E, Hü bscher SG. Antibioticassociated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994;20(1):112-6.
37. Schwarze C, Schmitz V, Fischer HP, Sauerbruch T, Spengler U. Vanishing bile duct syndrome associated with elevated pancreatic enzymes after short-term administration of amoxicillin. Eur J Gastroenterol Hepatol. 2002;14(11):1275-7.
38. Madroñero AB, Porcel JM, Bielsa S. Hepatotoxicity induced by amoxicillin. Rev Esp Enferm Dig. 2007;99(3):173-4.
39. Romney R, Biour M, Belloula D, Elbaz D, Carriere J, Cadranel JF. Amoxicillin induced acute hepatitis. Gastroenterol Clin Biol. 2004;28(5):505-6.
40. Garci{dotless}́a Rodri{dotless}́guez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med. 1996;156(12):1327-32.
41. Kö klü S, Kö ksal AS, Asil M, Kiyici H, Coban S, Arhan M. Probable sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother. 2004;38(12):2055-8.
42. Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol. 2007;19(1):15-20.
43. Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol. 2010;70(5):721-8.
44. Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182-9.
45. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res. 2001;6(4):139-49.
46. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006;44(4):850-6;
47. Andrade RJ, Lucena MI, Alonso A, Garci{dotless}́a-Cortes M, Garci{dotless}́a-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603-12;
48. Ten Pass A, Quinn EL. Cholestatic hepatitis following the administration of sodium oxacillin. JAMA. 1965;191:674-5.
49. Freedman M. Oxacillin: apparent hematologic and hepatic toxicity. Rocky Mt Med J. 1965;62:34-6.
50. Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr. 1976;89(5):835-8.
51. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis. 2002;34(1):50-4.
52. Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. South Med J. 2002;95(6):650-2.
53. Nahata MC, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. Dev Pharmacol Ther. 1982;4(3-4):117-23.
54. Lee CY, Chen PY, Huang FL, Chi CS. Reversible oxacillinassociated hepatitis in a 9-month-old boy. J Paediatr Child Health. 2008;44(3):146-8.
55. Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60(1):76-82.
56. Li L, Jick H, Jick SS. Updated study on risk of cholestatic liver disease and flucloxacillin. Br J Clin Pharmacol. 2009; 68(2):269-70.
57. Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf. 2003;2(3):287-304.
58. Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology. 2010;51(5): 1656-64.
59. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasisin children. Lancet. 1988;2(8625):1411-3.
60. Papadopoulou F, Efremidis S, Karyda S, Badouraki M, Karatza E, Panteliadis C, et al. Incidence of ceftriaxoneassociated gallbladder pseudolithiasis. Acta Paediatr. 1999;88(12):1352-5.
61. Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis. World J Gastroenterol. 2009;15(21):2669-71.
62. Bell MJ, Stockwell DC, Luban NL, Shirey RS, Shaak L, Ness PM, et al. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr Crit Care Med. 2005;6(3):363-6.
63. Longo F, Hastier P, Buckley MJ, Chichmanian RM, Delmont JP. Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol. 1998;93(5):836-7.
64. Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease'. South Med J. 1991;84(10):1263-5.
65. Kaur I, Singh J. Cholestatic hepatitis with intravenous ceftriaxone. Indian J Pharmacol. 2011;43(4):474-5.
66. Ekiz F, Usküdar O, Simsek Z, Yü ksel I, Basar O, Altinbas A, et al. Cefuroxime axetil-induced liver failure. Ann Hepatol. 2010;9(3):306.
67. Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol. 2004;38(9):833.
68. Schreiber C, May B. Cholestasis in imipenem/cilastatin treatment. Z Gastroenterol. 1993;31(Suppl 2):76-7.
69. Quattropani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver. 2001;21(3):213-6.
70. Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome. Pharmacotherapy. 2010;30(9):953.
71. Johnson DF, Jr, Hall WH. Allergic hepatitis caused by propionyl erythromycin ester of lauryl sulfate. N Engl J Med. 1961;265:1200-2.
72. Havens WP, Jr. Cholestatic jaundice in patients treated with erythromycin estolate. JAMA. 1962;180:30-2;
73. Committee on Safety of Medicines. Jaundice and erythromycin, (adverse reactions series no. 10). London: DHSS; 1973.
74. Strieker BH, Spoelstra P, editors. Drug-induced hepatic injury: a comprehensive survey of the literature on adverse drug reactions up to January 1985. Amsterdam: Elsevier; 1985. p. 153-4.
75. Inman WH, Rawson NS. Erythromycin estolate and jaundice. Br Med J (Clin Res Ed). 1983;286(6382):1954-5.
76. Derby LE, Jick H, Henry DA, Dean AD. Erythromycinassociated cholestatic hepatitis. Med J Aust. 1993;158(9):600-2.
77. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med. 1993;119(7 Pt 1):576-83.
78. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481-9.
79. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992;15(2): 244-51.
80. Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med. 1990;150(1):215-6.
81. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci. 1979;24(5):385-96.
82. Krowchuk D, Seashore JH. Complete biliary obstruction due to erythromycin estolate administration in an infant. Pediatrics. 1979;64(6):956-8.
83. Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol. 2005;39(8):743-4.
84. Horn S, Aglas F, Horina JH. Cholestasis and liver cell damage due to hypersensitivity to erythromycin stearate recurrence following therapy with erythromycin succinate. Wien Klin Wochenschr. 1999;111(2):76-7.
85. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother. 1985;16(Suppl A):181-94.
86. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. 1999;20(1):25-41.
87. Baciewicz AM, Al-Nimr A, Whelan P. Azithromycin-induced hepatoxicity. Am J Med. 2005;118(12):1438-9.
88. Lockwood AM, Cole S, Rabinovich M. Azithromycininduced liver injury. Am J Health Syst Pharm. 2010;67(10):810-4.
89. Brown BA, Wallace RJ, Jr, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis. 1995;20(4):1073-4.
90. Fox JC, Szyjkowski RS, Sanderson SO, Levine RA. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol. 2002;42(6):676-80.
91. Masiá M, Gutiérrez F, Jimeno A, Navarro A, Borrás J, Matarredona J, et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med. 2002;162(4):474-6.
92. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krähenbühl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother. 2003;37(1):57-60.
93. Lucena MI, Andrade RJ, Sanchez-Martinez H, Perez-Serrano JM, Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J Gastroenterol. 1998;93(11):2309-11.
94. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med. 1991;91(6A):153S-61S.
95. Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H, Kloppel G. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol. 1995;23(6):759-60.
96. Labowitz JK, Silverman WB. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci. 1997;42(1):192-4.
97. Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol. 2002;37(5):696-9.
98. Goetz M, Galle PR, Schwarting A. Non-fatal acute liver injury possibly related to high-dose ciprofloxacin. Eur J Clin Microbiol Infect Dis. 2003;22(5):294-6.
99. Fuchs S, Simon Z, Brezis M. Fatal hepatic failure associated with ciprofloxacin. Lancet. 1994;343(8899):738-9.
100. Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother. 1992;26(5):636-9.
101. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy. Chemotherapy. 2001;47(Suppl 3):32-7.
102. Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy. 2001;47(Suppl 3):9-14.
103. Figueira-Coelho J, Pereira O, Picado B, Mendonça P, Neves-Costa J, Neta J. Acute hepatitis associated with the use of levofloxacin. Clin Ther. 2010;32(10):1733-7.
104. Food and Drug Administration. Levaquin: highlights of prescribing information [Internet]. Silver Spring (MD): FDA; 2008 [cited 2012 Jul 22]. Available from: http://www. accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_0206 35s57_020634s52_lbl.pdf
105. Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN. Possible levofloxacin induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis. 2001;33(12):2088-90.
106. Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. J Hepatol. 2001;35(2):308-9.
107. Schwalm JD, Lee CH. Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient. CMAJ. 2003;168(7):847-8.
108. Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. Ann Pharmacother. 2005;39(10):1737-40.
109. Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JR, Lavi{dotless}́n AC, Mones JC, et al. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumonia infection. Clin Ther. 2009;31(5):1014-9.
110. Björnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol. 2000;95(12):3662-4.
111. Jones SE, Smith RH. Quinolones may induce hepatitis. BMJ. 1997;314(7084):869.
112. González Carro P, Huidobro ML, Zabala AP, Vicente EM. Fatal subfulminant hepatic failure with ofloxacin. Am J Gastroenterol. 2000;95(6):1606.
113. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther. 2004;26(7):940-50.
114. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf. 2005;28(5):443-52.
115. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66(7):1431-46.
116. Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito I, Milano R. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics. 2010;126(5):e1253-6.
117. European Medicines Agency. Moxifloxacin: European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines [Internet]. London: EMA; 2010 [cited 2012 Jul 22]. Available from: http://www.ema. europa.eu/ema/index.jsp?curl5pages/news_and_events/news/ 2010/08/news_detail_001068.jsp&mid5WC0b01ac058004d5c1
118. Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury: review of the literature and report of a case due to sulfamethoxazole. N Engl J Med. 1967;277(15):785-8.
119. Jick H, Derby LE. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. 1995;15(4):428-32.
120. Bell TL, Foster JN, Townsend ML. Trimethoprim-sulfamethoxazole-induced hepatotoxicity in a pediatric patient. Pharmacotherapy. 2010;30(5):539.
121. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100(4):495-9.
122. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol. 1994;89(8):1230-4.
123. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol. 1997;92(1):167-9.
124. Espiritu CR, Kim TS, Levine RA. Granulomatous hepatitis associated with sulfadimethoxine hypersensitivity. JAMA. 1967;202(10):985-8.
125. Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med. 1985;102(5):722.
126. Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am J Gastroenterol. 1989;84(12):1577-9.
127. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology. 1981;80(4):816-9.
128. Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D, et al. Fulminant hepatic failure in a child as a potential adverse effect of trimethoprim-sulphamethoxazole. Eur J Pediatr. 1995;154(7):530-3.
129. Ilario MJ, Ruiz JE, Axiotis CA. Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprimsulfamethoxazole. Arch Pathol Lab Med. 2000;124(12):1800-3.
130. Konttinen A, Perä salo JO, Eisalo A. Sulfonamidehepatitis. Acta Med Scand. 1972;191(5):389-91.
131. Lepper MH, Wolfe CK, Zimmerman HJ, Caldwell ER, Jr, Spies HW, Dowling HF. Effect of large doses of aureomycin on human liver. AMA Arch Intern Med. 1951;88(3):271-83.
132. Schultz JC, Adamson JS, Jr, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med. 1963;269:999-1004.
133. Peters RL, Edmondson HA, Mikkelsen WP, Tatter D. Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. Am J Surg. 1967;113(5):622-32.
134. Robinson MJ, Rywlin AM. Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis. 1970;15(9):857-62.
135. Björnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol. 1997;32(4): 390-5.
136. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483-7.
137. Chavant F, Lafay-Chebassier C, Beauchant M, Perault-Pochat MC. Doxycycline induced hepatitis. Gastroenterol Clin Biol. 2008;32(10):825-7.
138. Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol. 2008;20(8):796-9.
139. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312(7024):169-72.
140. Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23(4):333-49.
141. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54-66.
142. Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Am J Clin Pathol. 2000;114(4):591-8.
143. Edoute Y, Karmon Y, Roguin A, Ben-Ami H. Fatal liver necrosis associated with the use of nitrofurantoin. Isr Med Assoc J. 2001;3(5):382-3.
144. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology. 1981;18(2):177-8.
145. Stricker BH, Blok AP, Claas FH, van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8(3):599-606.
146. D'Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm. 1985;19(7-8):540-7.
147. Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol. 2004;172(2):448-53.
148. Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycinassociated hepatotoxicity. Am J Med. 1974;57(4):627-30.
149. Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J Gastroenterol. 2007;13(40):5408-10.
150. Sahagún Flores JE, Soto Ortiz JA, Tovar Méndez CE, Cárdenas Ochoa EC, Hernández Flores G. Stevens-Johnson syndrome plus intrahepatic cholestasis caused by clindamycin or chlorpheniramine. Dermatol Online J. 2009;15(5):12.
151. Cadle RM, Mansouri MD, Darouiche RO. Vancomycininduced elevation of liver enzyme levels. Ann Pharmacother. 2006;40(6):1186-9.
152. Mennicke M, Zawodniak A, Keller M, Wilkens L, Yawalkar N, Stickel F, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant. 2009;9(9):2197-202.
153. Chen Y, Yang XY, Zeckel M, Killian C, Hornbuckle K, Regev A, et al. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and metaanalysis. Drug Saf. 2011;34(1):73-82.
154. de Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, et al. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6(3):322-6.
155. Food and Drug Administration. Ketek: product label information [Internet]. Silver Spring (MD): FDA; 2004 [cited 2012 Jul 22]. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2004/21144_ketek_lbl.pdf
156. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144(6):415-20.
157. Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin Ther. 2007;29(8):1725-9.
158. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513-39.
159. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009;49(1):250-7.
160. Bertino J, Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 2000;22(7):798-817.
161. Lucena MI, Andrade RJ, Rodrigo L, Salmerón J, Alvarez A, Lopez-Garrido MJ, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 2000;30(2):400-1.
162. European Medicines Agency. Public statement on trovafloxacin/ alatrofloxacin: recommendation to suspend the marketing authorisation in the European Union [Internet]. London: EMA; 2009 [cited 2012 Jul 22]. Available from: http://www. ema.europa.eu/docs/en_GB/document_library/Public_statement/ 2009/12/WC500018300.pdf
163. European Medicines Agency. Better medicines for children [Internet]. London: EMA; 2009 [cited 2013 Mar 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Other/2009/12/WC500026493.pdf
164. Liver injury by antibiotics. Br Med J. 1953;1(4813):777.
165. Shibl AM, Memish Z, Osoba A. Antibiotic resistance in developing countries. J Chemother. 2001;13(Suppl 1):40-4.
166. Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3(2):e16.
167. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;(1):CD002086;
168. Chiappini E, Regoli M, Bonsignori F, Sollai S, Parretti A, Galli L, et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther. 2011;33(1):48-58.
169. Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol. 2010;245(1):134-42.